Key result
TTNtv linked to ~21-fold higher odds of dilated cardiomyopathy, with clinical factors accelerating onset.
Why the study?
Do clinical risk factors and prophylactic medical therapy (beta-blockers or RAS inhibitors) affect the onset of dilated cardiomyopathy in subjects with TTNtv-related familial DCM?
Observational (n=3,158)
Yes
Do clinical risk factors and prophylactic medical therapy (beta-blockers or RAS inhibitors) affect the onset of dilated cardiomyopathy in subjects with TTNtv-related familial DCM?
Answers are grounded in this paper and cite their sources.
In patients with TTNtv-related familial DCM, clinical risk factors accelerate disease onset, while prophylactic treatment with beta-blockers or RAS inhibitors may significantly delay or prevent it.
Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur as incidental findings in the general population. This study investigated factors associated with the clinical manifestation of TTNtv. An international multicentre retrospective observational study was performed in families with TTNtv-related DCM. Shared frailty models were used to estimate associations of variant characteristics with lifetime risk of DCM, and logistic regression to estimate odds ratios (ORs) for individual-level clinical risk factor profiles (cardiac conditions, cardiovascular comorbidities, lifestyle) and DCM. A total of 3158 subjects in 1043 families with TTNtv-related DCM were studied. TTNtv-positive subjects were 21-fold more likely to develop DCM [OR, 21.21; 95% confidence interval (CI), 14.80-30.39]. Disease onset was earlier in males, but was similar for TTNtv of different types and locations. The presence of clinical risk factors was associated with earlier DCM onset (OR, 3.41; 95% CI, 2.06-5.64), with a prior history of atrial fibrillation having a two-fold increased odds of DCM (OR, 2.05; 95% CI, 1.27-3.32). The prevalence of clinical risk factors increased with age; however, the strength of the DCM association was greatest for young-onset (<30 years) disease (OR, 4.75; 95% CI, 2.35-9.60). Administration of beta-adrenergic receptor or renin-angiotensin system-blocking drugs prior to overt DCM was associated with 87% reduced odds of DCM (OR, .13; 95% CI, .08-.23). Disease onset in TTNtv-associated familial DCM is dependent on individual patient context and is potentially modifiable by risk factor management and prophylactic therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2025) conducted an observational in TTNtv-related dilated cardiomyopathy (n=3,158). Truncating variants in the TTN gene (TTNtv) vs. TTNtv-negative subjects was evaluated on Development of dilated cardiomyopathy (OR 21.21, 95% CI 14.80-30.39). TTNtv-positive subjects had a 21-fold increased odds of developing dilated cardiomyopathy (OR 21.21; 95% CI 14.80-30.39), with clinical risk factors further accelerating disease onset.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: